BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33912162)

  • 1. The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies.
    Malaney P; Velasco-Estevez M; Aguilar-Garrido P; Aitken MJL; Chan LE; Zhang X; Post SM; Gallardo M
    Front Immunol; 2021; 12():634584. PubMed ID: 33912162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas.
    Gallardo M; Malaney P; Aitken MJL; Zhang X; Link TM; Shah V; Alybayev S; Wu MH; Pageon LR; Ma H; Jacamo R; Yu L; Xu-Monette ZY; Steinman H; Lee HJ; Sarbassov D; Rapado I; Barton MC; Martinez-Lopez J; Bueso-Ramos C; Young KH; Post SM
    J Natl Cancer Inst; 2020 Jan; 112(1):95-106. PubMed ID: 31077320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
    Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
    Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
    Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
    Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
    Högstrand K; Grandien A
    Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression.
    Barboro P; Ferrari N; Balbi C
    Cancer Lett; 2014 Oct; 352(2):152-9. PubMed ID: 25016060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant hnRNP K expression: All roads lead to cancer.
    Gallardo M; Hornbaker MJ; Zhang X; Hu P; Bueso-Ramos C; Post SM
    Cell Cycle; 2016 Jun; 15(12):1552-7. PubMed ID: 27049467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
    Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
    Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
    Rodig SJ; Kutok JL; Paterson JC; Nitta H; Zhang W; Chapuy B; Tumwine LK; Montes-Moreno S; Agostinelli C; Johnson NA; Ben-Neriah S; Farinha P; Shipp MA; Piris MA; Grogan TM; Pileri SA; Gascoyne RD; Marafioti T
    Haematologica; 2010 Dec; 95(12):2056-62. PubMed ID: 20823132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.
    Leskov I; Pallasch CP; Drake A; Iliopoulou BP; Souza A; Shen CH; Schweighofer CD; Abruzzo L; Frenzel LP; Wendtner CM; Hemann MT; Chen J
    Oncogene; 2013 Feb; 32(8):1066-1072. PubMed ID: 22484426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syntheses and evaluation of new Quinoline derivatives for inhibition of hnRNP K in regulating oncogene c-myc transcription.
    Shu B; Zeng P; Kang S; Li PH; Hu D; Kuang G; Cao J; Li X; Zhang M; An LK; Huang ZS; Li D
    Bioorg Chem; 2019 Apr; 85():1-17. PubMed ID: 30599408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.
    Mensink M; Anstee NS; Robati M; Schenk RL; Herold MJ; Cory S; Vandenberg CJ
    Cell Death Differ; 2018 Mar; 25(4):797-808. PubMed ID: 29339775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation of mature mouse B cells into malignant plasma cells in vitro via introduction of defined genetic elements.
    Högstrand K; Lindvall JM; Sundblad A; Grandien A
    Eur J Immunol; 2019 Mar; 49(3):454-461. PubMed ID: 30664244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma.
    Winkler R; Piskor EM; Kosan C
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.
    Sabò A; Kress TR; Pelizzola M; de Pretis S; Gorski MM; Tesi A; Morelli MJ; Bora P; Doni M; Verrecchia A; Tonelli C; Fagà G; Bianchi V; Ronchi A; Low D; Müller H; Guccione E; Campaner S; Amati B
    Nature; 2014 Jul; 511(7510):488-492. PubMed ID: 25043028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-Induced Replication Stress.
    Spehalski E; Capper KM; Smith CJ; Morgan MJ; Dinkelmann M; Buis J; Sekiguchi JM; Ferguson DO
    Cancer Res; 2017 Oct; 77(19):5327-5338. PubMed ID: 28819025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells.
    Hunter JE; Campbell AE; Kerridge S; Fraser C; Hannaway NL; Luli S; Ivanova I; Brownridge PJ; Coxhead J; Taylor L; Leary P; Hasoon MSR; Eyers CE; Perkins ND
    Biochem J; 2022 Oct; 479(19):2131-2151. PubMed ID: 36240067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
    Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
    Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myc suppression of Nfkb2 accelerates lymphomagenesis.
    Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
    BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.